Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Principia payoff

November 1, 2004 8:00 AM UTC

With one preclinical deal, Human Genome Sciences Inc. stands to have monetized its acquisition of Principia Pharmaceuticals Corp.

HGSI bought Principia in 2000 for $120 million in stock in order to gain access to its human albumin-based protein fusion technology. Last week, GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) received exclusive worldwide rights to HGSI's Albugon fusion of glucagon-like peptide (GLP-1) and human albumin in exchange for as much as $183 million in upfront and milestone payments. HGSI, which is responsible for manufacturing the fusion protein for Phase I and II trials, also is eligible for royalties...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article